Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director | May 29, 2026 | June 01, 2026 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| CHIMERIX INCCMRX · Entity 80651 | Director | June 20, 2019 | June 24, 2019 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | October 01, 2026 | October 03, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date May 29, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,148 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 8,107 · Balance 12,148 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Exercise / conversion · Disposed 8,107 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,311 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 9,311 · Balance 9,311 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended. |
| Director Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2036-05-28 | Direct | 16,004 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 16,004 · Balance 16,004 F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3: The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4: The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,873 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 60,414 · Balance 109,873 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
CHIMERIX INC
Report date June 20, 2019 · Filed June 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-19 | Direct | 21,000 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,390 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 151 · Balance 3,390 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
HALOZYME THERAPEUTICS, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 1,169 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,169 · Balance 1,169 F1: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $106.94 · Expires 2036-10-01 | Direct | 1,775 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 1,775 · Balance 1,775 F2: Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
F2: Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,081 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 3,081 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,460 | $258.28 | $377,093.76 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 6 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,501 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.01 to $258.93, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,604 | $257.30 | $927,302.35 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 5 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,961 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.01 to $258.00, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 7,401 | $256.50 | $1,898,370.56 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,565 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.01 to $257.00, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,809 | $255.64 | $1,740,629.61 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,966 F1 · kind: (1) These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.01 to $256.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 1,577 | $105.08 | $165,711.16 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 20,000 | $100.45 | $2,009,000.00 |
DisclosureSEC source: 0000899243-24-000243 · doc4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $43.74 | $437,410.00 |
DisclosureSEC source: 0001415889-23-012257 · form4-08152023_080821.xml · nonDerivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,503 F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.54 to $44.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 20:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $43.71 | $437,110.00 |
DisclosureSEC source: 0001415889-23-012257 · form4-08152023_080821.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,503 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $43.63 to $43.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 1,198 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016057 · doc4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,198 F1 · kind: Represents a grant of restricted stock units, which vest on June 15, 2024, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · derivative · entry 8 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,652 Underlying: Common Stock · 6,652 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,045 | $0.00 Strike: $23.90 | $0.00 |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · derivative · entry 7 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,045 Underlying: Common Stock · 11,045 shares Expires 2033-05-31 F3 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · derivative · entry 6 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,552 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · nonDerivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007689 · form4-05092023_100552.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007689 · form4-05092023_100552.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,503 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 13:12 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 60,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000422 · wf-form4_167294235465620.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 10:30 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 35,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024219 · wf-form4_166212898622803.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 10:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 9,470 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0000899243-22-023230 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 14:46 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001628280-22-017338 · wf-form4_165540519195576.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035668 · doc4.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,552 Underlying: Common Stock · 8,552 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 00:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 14,368 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-22-035668 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,368 Underlying: Common Stock · 14,368 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · derivative · entry 5 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 07, 2022 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 6,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · nonDerivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| May 05, 2022 Filed May 7, 2022 00:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Unit | 6,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002908 · edgar.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,438 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:39 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 809 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000412 · wf-form4_164147994091373.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 809 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: The RSUs granted on July 1, 2021 vest in full on January 4, 2022. F3 · derivative.expiration_date: The RSUs granted on July 1, 2021 vest in full on January 4, 2022. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:39 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 13,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000412 · wf-form4_164147994091373.xml · derivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021 F2 · derivative.expiration_date: The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021 Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:39 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 809 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000412 · wf-form4_164147994091373.xml · nonDerivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:39 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 13,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000412 · wf-form4_164147994091373.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:28 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045705 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809 Underlying: Common Stock · 809 shares Expires 2022-01-04 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043037 · doc4.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,391 Underlying: Common Stock · 6,391 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 11,637 | $0.00 Strike: $24.88 | $0.00 |
DisclosureSEC source: 0001209191-21-043037 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 Underlying: Common Stock · 11,637 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F2 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 22, 2021 Filed Jun 6, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-034695 · doc4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:03 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 12,489 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000899243-21-024669 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,489 Underlying: Common Stock · 12,489 shares Expires 2024-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 15, 2021 Filed Jul 7, 2021 20:23 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-045940 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-06-14 Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Unit | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004971 · edgar.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,232 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:32 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 13,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000090 · wf-form4_160988952610822.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,568 Underlying: Common Stock · 13,568 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs will vest in full upon the one year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs will vest in full upon the one year anniversary of the date of grant. Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 23:57 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,363 | $40.41 | $418,799.92 |
DisclosureSEC source: 0001179110-20-011427 · edgar.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,002 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.40 to $40.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 13, 2020 Filed Aug 13, 2020 22:43 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 34,337 | $29.12 | $999,893.44 |
DisclosureSEC source: 0001179110-20-009018 · edgar.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,365 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $29.00 to $29.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 3,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038977 · doc4.xml · derivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Underlying: Common Stock · 3,059 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. F3 · derivative.expiration_date: The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantDirector Stock Options (Right to Buy) · Derivative | 5,579 | $0.00 Strike: $52.73 | $0.00 |
DisclosureSEC source: 0001209191-20-038977 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,579 Underlying: Common Stock · 5,579 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 11:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0000899243-20-016992 · doc4.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 16:52 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001628280-20-009551 · wf-form4_159234074046391.xml · derivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $27.25 | $0.00 |
DisclosureSEC source: 0001209191-20-028940 · doc4.xml · derivative · entry 5 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $25.24 | $0.00 |
DisclosureSEC source: 0001209191-20-028940 · doc4.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 26,250 | $51.13 | $1,342,178.25 |
DisclosureSEC source: 0001209191-20-028940 · doc4.xml · nonDerivative · entry 3 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.975 to $51.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 15,000 | $27.25 | $408,750.00 |
DisclosureSEC source: 0001209191-20-028940 · doc4.xml · nonDerivative · entry 2 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 11,250 | $25.24 | $283,950.00 |
DisclosureSEC source: 0001209191-20-028940 · doc4.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 1, 2020 23:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005377 · edgar.xml · nonDerivative · entry 1 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,702 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 23:18 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001209191-19-049230 · doc4.xml · derivative · entry 4 Daly James M · CIK 0001560782 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.